 

Active ingredient: Atenolol 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 100 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 100 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional comments: 




_____________________________________________________________________________ 

 

Analytes to measure: Atenolol in plasma 

 

Bioequivalence based on (90% CI): Atenolol 

 

Waiver request of in-vivo testing: 25 mg and 50 mg based on (i) acceptable bioequivalence 
studies on the 100 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and 
(iii) proportional similarity of the formulations across all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 


